Business Context and Reporting Period
Akebia Therapeutics, Inc. (AKBA) filed a Form 8-K on July 15, 2022, reporting the entry into a material definitive agreement. The company is a biopharmaceutical firm incorporated in Delaware with principal offices in Cambridge, Massachusetts.
Key Financial Metrics and Transaction Details
The filing details a significant debt restructuring event involving the Second Amendment and Waiver to the Loan Agreement dated November 11, 2019. Key financial figures include:
- Tranche A Prepayment: $5,000,000 principal.
- Tranche B Prepayment: $20,000,000 principal.
- Prepayment Premiums: $500,000 aggregate.
- Total Cash Outflow: $25,500,000 (excluding accrued interest).
The filing does not provide current revenue, profit, cash flow, or margin data, as this is a current report focused on a specific contractual event rather than a periodic financial statement.
Material Changes and Agreement Provisions
In exchange for the prepayments, the Collateral Agent and Lenders agreed to the following material changes:
- Working Capital Facility Increase: Increased the amount of the working capital facility related to the Vifor License Agreement permitted under the Loan Agreement.
- Going Concern Waiver: Waived the requirement that the Company's Form 10-Q for the quarters ending June 30, 2022, and September 30, 2022, be free of "going concern" qualifications.
- Payment Waivers: Waived certain payments payable under the Loan Agreement specifically connected to the Tranche B prepayment.
Outlook, Risks, and Contingencies
The waiver of the "going concern" qualification requirement suggests the Company previously faced or anticipated scrutiny regarding its ability to continue operations without this specific covenant relief. The full text of the Second Amendment and Waiver is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
Investor Verification Checklist
- Verify the remaining principal balance on Tranche A and Tranche B loans post-prepayment.
- Review the upcoming Form 10-Q for the quarter ended June 30, 2022, to confirm the actual status of the "going concern" qualification and the full terms of the Second Amendment.
- Assess the impact of the $25.5 million cash outflow on the Company's remaining liquidity and runway.
- Confirm the specific increase amount for the Vifor working capital facility.